DOCSLIB.ORG

Direct Oral Anticoagulant Reversal: How, When and Issues Faced М Mikhail S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Direct Oral Anticoagulant Reversal: How, When and Issues Faced М Mikhail S Expert Review of Hematology ISSN: 1747-4086 (Print) 1747-4094 (Online) Journal homepage: http://www.tandfonline.com/loi/ierr20 У Direct oral anticoagulant reversal: how, when and issues faced М Mikhail S. Dzeshka, Daniele Pastori & Gregory Y.H. Lip Г To cite this article: Mikhail S. Dzeshka, Daniele Pastori & Gregory Y.H. Lip (2017) Direct oral anticoagulant reversal: how, when and issues faced, Expert Review of Hematology, р10:11, 1005-1022, DOI: 10.1080/17474086.2017.1379896 To link to this article: http://dx.doi.org/10.1080/17474086.2017.1379896Г Accepted author version posted online: 13 Sep 2017. й Published online: 22 Sep 2017. Submit your article to this journal и Article views: 72 р View related articles о т View Crossmark data и з о п е Р Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierr20 Download by: [Dr Mikhail Dzeshka] Date: 29 October 2017, At: 04:40 EXPERT REVIEW OF HEMATOLOGY, 2017 VOL. 10, NO. 11, 1005–1022 https://doi.org/10.1080/17474086.2017.1379896 REVIEW Direct oral anticoagulant reversal: how, when and issues faced Mikhail S. Dzeshkaa,b, Daniele Pastoria,c and Gregory Y.H. Lipa,d aInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; bGrodno State Medical University, Grodno, Belarus; cDepartmentУ of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy; dAalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark ABSTRACT ARTICLE HISTORY Introduction: The number of atrial fibrillation (AF) patients requiring thrombo-prophylaxis with oral Received 2 AugustМ 2017 anticoagulation is greatly increasing. The introduction of non-vitamin K oral anticoagulants (NOACs) in Accepted 12 September 2017 addition to standard therapy with dose-adjusted warfarin has increased the therapeutic options for AF KEYWORDS patients. Despite a generally better safety profile of the NOACs, the risk of major bleedings still persists, Non-vitaminГ K oral and the management of serious bleeding is a clinical challenge. anticoagulants; bleeding; Areas covered: In the current review, risk of major bleeding in patients taking NOACs and general reversal agents; approaches to manage bleeding depending on severity, with a particular focus on specific reversal idarucizumab; andexanet α; agents, are discussed. рciraparantag; prothrombin Expert commentary: Due to short half-life of NOACs compared to warfarin, discontinuation of drug, complex concentrate mechanical compression, and volume substitution are considered to be sufficient measures in most of bleeding cases. In case of life-threatening bleeding or urgent surgery, hemostasis can be achieved with non-specific reversal agents (prothrombin complex concentrates) in patients treated with factorГ Xa inhibitor until specific antidotes (andexanet α and ciraparantag) will receive approval. Thus far, idar- ucizumab has been the only reversal agent approved for dabigatran. й 1. Introduction The fixed-dose non-vitamin K oral anticoagulants (NOACs) were developed to overcome these issues and to improve Atrial fibrillation (AF) is the most common sustained arrhyth- adherenceи to OAC. Thus far, the NOACs included a direct mia, and it confers increased risk of stroke and systemic thrombin inhibitor dabigatran etexilate and factor Xa (FXa) embolism when one or more additional stroke risk factors inhibitors, namely, rivaroxaban, apixaban, and edoxaban are present [1,2]. The CHA DS -VASc score includes a cluster 2 2 р[9,11]. The safety and efficacy of each of the NOACs were of clinical risk factors associated with increased risk of throm- compared to warfarin in large phase 3 prospective rando- boembolism, such as congestive heart failure, hypertension, mized clinical trials [12–15]. All the NOACs showed to be at older age, diabetes mellitus, history of stroke or systemic о least as effective as warfarin for stroke prevention, along with embolism, vascular disease, and female sex [3]. This score is a better safety profile [12–15]. Thus, a significant reduction in recommended by guidelines as the preferred decision-making the rate of intracranial hemorrhage (ICH) was found for all tool to identify patients requiring oral anticoagulationт (OAC); Downloaded by [Dr Mikhail Dzeshka] at 04:40 29 October 2017 NOACs compared to warfarin (Table 1). Despite this favorable the use of CHA DS -VASc over CHADS score significantly 2 2 2 profile of NOACs, unavailability of specific reversal agents to improved stroke risk stratification in AF [4] by identifying manage life-threatening bleeding or to proceed without truly low-risk patients (rate of thromboembolic events < 1%/ и delays with emergency surgery has been raised as a clinical year) who do not need antithrombotic therapy [5,6]. issue [9,11]. Other indications for treatment with NOACs are Stroke prevention is pivotal component of AF management represented by acute [17] and chronic venous thromboembo- with OAC being the only effective treatmentз [5–7]. While OAC lism [18], where NOACs showed broadly similar effectiveness with warfarin is still a valid option for AF patients when quality compared to warfarin, with lower bleeding events [19–21]as of anticoagulant control is good (i.e. time in therapeutic range well as prophylaxis of venous thromboembolism in adult >70%) [8], many limitationsо of therapy with warfarin were patients hospitalized for an acute medical illness who are at acknowledged. Indeed, clinical challenges for warfarin therapy risk for thromboembolic complications [22]. are represented by its narrow therapeutic range, variability of Indications for the NOACs can be further expanded after anticoagulant effectп over time, requirement of regular labora- results of ongoing trials addressing OAC in peripheral artery tory monitoring, numerous drug interactions, slow onset, and disease, heart failure, and secondary prevention of recurrent prolonged half-life [7,9]. As result, a significant proportion of strokes in patients with ischemic stroke of undetermined AF patients withе indication to receive OAC are not adequately source will become available [23]. treatedР or not treated at all [10]. CONTACT Gregory Y.H. Lip [email protected] Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham B18 7QH, UK © 2017 Informa UK Limited, trading as Taylor & Francis Group У М Г 1006 р M. S. DZESHKA ET AL. Г Table 1. Summary of bleedings in phase 3 clinical trials with NOACs in AF patients. NOAC Dabigatran [12,16] Rivaroxaban [13] Apixaban [14] Edoxaban [15] Patients (n) 18.113 й 14.264 18.201 21.105 Age (years) 71 73 70 72 CHADS2 score 2.1 3.5 2.1 2.8 Dosing arm (mg) 110 bid 150 bid 20 (15) qd 5 (2.5) bid 30 (15) qd 60 (30) qd Prior vitamin K antagonist treatment (%) 50 и 62 57 59.2 58.8 Mean TTR, warfarin arm (%) 64 55 62 68.4 % of patients per year and HR (95% CI) for NOACs vs. warfarin Major bleeding NOAC 2.92 3.4 3.6 2.13 1.61 2.75 Warfarin 3.61 р 3.61 3.4 3.09 3.43 3.43 HR (95%CI) 0.80 (0.70–0.93) 0.94 (0.82–1.08) 1.04 (0.90–1.20) 0.69 (0.60–0.80) 0.47 (0.41–0.55) 0.80 (0.71–0.91) Major or clinically relevant nonmajor bleeding NOAC NA NA 14.9 4.07 7.97 11.10 Warfarin 14.5 6.01 13.02 13.02 HR (95%CI) о 1.03 (0.96–1.11) 0.68 (0.61–0.75) 0.62 (0.57–0.67) 0.86 (0.80–0.92) Life-threatening bleeding NOAC 1.27 1.52 0.8 NR 0.25 0.40 Warfarin 1.87 1.87 1.2a 0.78 0.78 HR (95%CI) 0.67 (0.55–0.83) 0.81 (0.67–0.99) 0.69 (0.53–0.91) 0.32 (0.23–0.46) 0.51 (0.38–0.70) Intracranial hemorrhage NOAC т 0.23 0.3 0.5 0.33 0.26 0.39 Downloaded by [Dr Mikhail Dzeshka] at 04:40 29 October 2017 Warfarin 0.74 0.74 0.70 0.80 0.85 0.85 HR (95%CI) 0.30 (0.19–0.45) 0.41 (0.28–0.60) 0.67 (0.47–0.93) 0.42 (0.30–0.58) 0.30 (0.21–0.43) 0.47 (0.34–0.63) Gastrointestinal bleeding NOAC 1.12 1.51 3.2 0.76 0.82 1.51 Warfarinи 1.02 1.02 2.20 0.86 1.23 1.23 HR (95%CI) 1.09 (0.85–1.39) 1.49 (1.19–1.88) 1.47 (1.20–1.81) 0.88 (0.67–1.14) 0.67 (0.53–0.83) 1.23 (1.02–1.50) Any bleeding NOAC 14.62 16.42 NR 18.1 10.68 14.15 зWarfarin 18.15 18.15 25.8 16.40 16.40 HR (95%CI) 0.78 (0.74–0.83) 0.91 (0.86–0.97) 0.71 (0.68–0.75) 0.66 (0.62–0.71) 0.87 (0.82–0.92) aCritical bleeding. bid: twice daily; CHADS2: congestive heart failure, hypertension, age >75 years, diabetes mellitus, stroke or transient ischemic attack (2 points); CI: confidence interval; NOAC: non-vitamin K oral anticoagulant; NR: not reported; qd: once daily; TTR: time in therapeuticо range. п е Р EXPERT REVIEW OF HEMATOLOGY 1007 The aim of the current review is to provide a summary of Real-world data further reaffirmed the safety and efficacy of current knowledge on (1) assessment of risk of major bleeding the NOACs observed in the randomized trials [20,21,28,39–42]. in patients taking NOACs, (2) management of bleeding with a However, high bleeding risk is not a reason to give up OAC particular focus on use of specific reversal agents, and (3) the with the purpose of stroke prevention [5].
Load more

Recommended publications
  • Reversal of Oral Anticoagulation in Patients with Acute Intracerebral Hemorrhage Joji B
    Kuramatsu et al. Critical Care (2019) 23:206 https://doi.org/10.1186/s13054-019-2492-8 REVIEW Open Access Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage Joji B. Kuramatsu* , Jochen A. Sembill and Hagen B. Huttner Abstract In light of an aging population with increased cardiovascular comorbidity, the use of oral anticoagulation (OAC) is steadily expanding. A variety of pharmacological alternatives to vitamin K antagonists (VKA) have emerged over recent years (direct oral anticoagulants, DOAC, i.e., dabigatran, rivaroxaban, apixaban, and edoxaban) which show a reduced risk for the occurrence of intracerebral hemorrhage (ICH). Yet, in the event of ICH under OAC (OAC-ICH), hematoma characteristics are similarly severe and clinical outcomes likewise substantially limited in both patients with VKA- and DOAC-ICH, which is why optimal acute hemostatic treatment in all OAC-ICH needs to be guaranteed. Currently, International Guidelines for the hemostatic management of patients with OAC-ICH are updated as several relevant large-sized observational studies and recent trials have established treatment approaches for both VKA- and DOAC-ICH. While the management of VKA-ICH is mainly based on the immediate reversal of elevated levels of international normalized ratio using prothrombin complex concentrates, hemostatic management of DOAC-associated ICH is challenging requiring specific antidotes, notably idarucizumab and andexanet alfa. This review will provide an overview of the latest studies and trials on hemostatic reversal agents and timing and summarizes the effects on hemorrhage progression and clinical outcomes in patients with OAC-ICH. Keywords: Intracerebral hemorrhage, Anticoagulation reversal, Tranexamic acid, Ciraparantag, Desmopressin Introduction importantly have a greater frequency of hematoma ex- Of all stroke sub-types, intracerebral hemorrhage (ICH) pansion (HE), all of which are significant outcome pre- constitutes roughly 15% and is associated with the worst dictors determining an even poorer prognosis [11–13].
    [Show full text]
  • Oral Anticoagulants
    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
    [Show full text]
  • 76. Which of the Following Is Incorrect Based on the 2018 ASRA Checklist for Managing Local Anesthetic Systemic Toxicity?
    76. Which of the following is incorrect based on the 2018 ASRA Checklist for managing Local Anesthetic Systemic Toxicity? A. The upper limit of lipid emulsion dosing is 12mL/kg B. Monitoring should be at least 4-6 hours after a cardiovascular event or at least 2 hours after a limited CNS event C. 20% lipid emulsion should be used as the initial drug at the first sign of a serious LAST Event D. Epinephrine doses of > 1mcg/kg are recommended 77. Which of the following statements is NOT true with regard to the management of new oral anticoagulants? A. Rivaroxaban (Xarelto) and Apixaban (Eliquis) should be held for at least 72 hours prior to neuraxial block B. Dabigatran (Pradaxa) should be held for 24 to 48 hours prior to neuraxial block in a patient with a compromised GFR C. Dabigatran can be reversed by the monoclonal antibody idarucizumab D. Factor Xa inhibitors, Rivaroxaban and Apixaban, can be effectivelY reversed with andexanet alfa 78. Which answer the correct spread of local anesthetic for an Erector Spinae Plane Block performed at the T5 level? A. Spread between the erector spinae muscle and rhomboid muscle B. Spread lateral to the transverse process, superficial to the erector spinae muscle C. Spread deep to the erector spinae muscle at the transverse process D. Spread deep to the costotransverse ligament, pushing the pleura ventrallY 79. When assessing the lungs with ultrasound, which of the following signs are suggestive a pneumothorax: A. Absence of lung sliding B. Presence of “comet tails” C. Absence of a “lung point” D.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Management of Bleeding with Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents
    NEW DRUGS AND DEVICES Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents ABSTRACT: Vitamin K antagonists are commonly used by clinicians Downloaded from to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition to familiarity with the dosing and monitoring Christian T. Ruff, MD, of vitamin K antagonists, clinicians are accustomed to using vitamin K if MPH Robert P. Giugliano, MD, there is a need to reverse the anticoagulant effect of vitamin K antagonists. SM There are now 4 new non–vitamin K antagonist oral anticoagulants (NOACs) Elliott M. Antman, MD http://circ.ahajournals.org/ that are attractive alternatives to vitamin K antagonists. Despite similar or lower rates of serious bleeding with NOACs in comparison with warfarin, there is a pressing need for strategies to manage bleeding when it does occur with NOACs and to reverse the pharmacological effect of these agents if needed. Important steps in minimizing bleeding risks with NOACs include dose adjustment of the agents in the setting of renal dysfunction and avoidance of the concomitant use of other antithrombotic agents if by MEREDITH HURT on September 28, 2016 feasible. Laboratory measurement of the anticoagulant effect of NOACs is best accomplished with specialized assays, although some of the more widely available coagulation tests can provide information that is potentially useful to clinicians. Nonspecific hemostatic agents such as prothrombin complex concentrates and recombinant factor VIIa can be used to reverse the effect of NOACs. More specific reversing agents include the approved humanized monoclonal antibody fragment idarucizumab for reversing the effects of dabigatran, the investigational factor Xa decoy andexanet alfa, and the synthetic small molecule ciraparantag.
    [Show full text]
  • Four-Factor Prothrombin Complex Concentrate Improves Thrombin
    Schenk et al. Thrombosis Journal (2018) 16:1 DOI 10.1186/s12959-017-0158-9 RESEARCH Open Access Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial Bettina Schenk1* , Stephanie Goerke2,3, Ronny Beer4, Raimund Helbok4, Dietmar Fries1 and Mirjam Bachler1,5 Abstract Background: Direct oral anticoagulants (DOACs) pose a great challenge for physicians in life-threatening bleeding events. The aim of this study was to test the efficacy of reversing the DOAC rivaroxaban using four-factor PCC (prothrombin complex concentrate), a non-specific reversing agent. Methods: Patients with life-threatening bleeding events during rivaroxaban treatment were included and administered 25 U kg−1 of PCC. Blood samples were collected immediately prior to as well as after PCC treatment at predefined time intervals. The primary endpoint was defined as the difference in thrombin generation (TG) parameters ETP (endogenous thrombin potential) and Cmax (peak thrombin generation) prior to and ten minutes subsequent to PCC treatment. Results: Thirteen patients, of whom the majority suffered from intra-cranial haemorrhage (ICH) or subdural haemorrhage (SDH), were included and administered PCC. The results show that the ETP (TG) significantly (p = 0.001) improved by 68% and Cmax (TG) by 54% (p = 0.001) during PCC treatment. In addition, the Quick value (prothrombin time: QuickPT) significantly improved by 28% and the activated partial thromboplastin time (aPTT) was PT decreased by 7% ten minutes after PCC administration. Cmax was reduced at baseline, but not ETP, aPTT or Quick . Lag time until initiation (TG, tlag), thromboelastometry clotting time (CTEXTEM) and time to peak (TG, tmax) correlated best with measured rivaroxaban levels and were out of normal ranges at baseline, but did not improve after PCC administration.
    [Show full text]
  • Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3
    Neurocrit Care https://doi.org/10.1007/s12028-019-00830-4 PHARMACOTHERAPY Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3 © 2019 Neurocritical Care Society Abstract The appropriate use of medications during Emergency Neurological Life Support (ENLS) is essential to optimize patient care. Important considerations when choosing the appropriate agent include the patient’s organ function, medication allergies, potential adverse drug efects, drug interactions, critical illness, and age-related pathophysi- ologic changes. Medications used during ENLS include hyperosmolar therapy, antiseizures, antithrombotics, antico- agulant reversal hemostatic agents, antishivering agents, neuromuscular blockers, antihypertensive agents, sedatives, vasopressors inotropes, and antimicrobials. This chapter focuses on key pharmacokinetic and pharmacodynamic characteristics, advantages and disadvantages, and clinical pearls of these therapies, thereby providing practitioners with essential drug information to optimize pharmacotherapy in acutely ill neurocritical care patients. Keywords: ENLS, Pharmacotherapy, Medication, Adverse drug event, Drug interaction Introduction provider optimize medication management in the acute Neurocritical care patient management is highly com- period of neurologic injury. plicated, especially when trying to optimize therapy dur- ing the acute injury. Pharmacologic management must Chapter Outline be carefully considered in order to minimize cognitive • Hyperosmolar
    [Show full text]
  • In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2020-09-01 In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution Alexandra A. Angheloiu Temple University Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Fluids and Secretions Commons, Hemic and Immune Systems Commons, Investigative Techniques Commons, Laboratory and Basic Science Research Commons, and the Pharmaceutical Preparations Commons Repository Citation Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. (2020). In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution. Open Access Articles. https://doi.org/10.1007/ s40268-020-00308-1. Retrieved from https://escholarship.umassmed.edu/oapubs/4354 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Drugs in R&D (2020) 20:217–223 https://doi.org/10.1007/s40268-020-00308-1 ORIGINAL RESEARCH ARTICLE In‑Vitro Sorbent‑Mediated Removal of Edoxaban from Human Plasma and Albumin Solution Alexandra A. Angheloiu1 · Yanglan Tan2,3 · Cristian Ruse4 · Scott A. Shafer2,3 · George O. Angheloiu5 Published online: 15 May 2020 © The Author(s) 2020 Abstract Background and Objective Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the efect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral anticoagulant.
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Role of Ciraparantag, Andexanet Alfa, and Idarucizumab
    Vascular Health and Risk Management Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab Tiffany Y Hu1 Abstract: Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack Vaibhav R Vaidya2 of commercially available reversal agents is a major barrier for mainstream use of these therapies. Samuel J Asirvatham2,3 Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse monoclonal antibody that binds dabigatran and reverses its anticoagulant 1Mayo Medical School, 2Division of Cardiovascular Diseases, Department effect. In a recent Phase III study (Reversal Effects of Idarucizumab on Active Dabigatran), a 5 g of Internal Medicine, 3Department of intravenous infusion of idarucizumab resulted in the normalization of dilute thrombin time in Pediatrics and Adolescent Medicine, 98% and 93% of the two groups studied, with normalization of ecarin-clotting time in 89% and Mayo Clinic, Rochester, MN, USA 88% patients. Two other antidotes, andexanet alfa (PRT064445) and ciraparantag (PER977) are also under development for reversal of NOACs. In this review, we discuss commonly encountered For personal use only. management issues with NOACs such as periprocedural management, laboratory monitoring of anticoagulation, and management of bleeding. We review currently available data regarding specific antidotes to NOACs with respect to pharmacology and clinical trials. Keywords: novel oral anticoagulant, dabigatran, idarucizumab, reversal Video abstract Introduction For decades, vitamin K antagonists such as warfarin were the only oral agents avail- able for long-term anticoagulation. Warfarin’s variable bioavailability and drug–drug interactions complicate achievement of therapeutic anticoagulation and necessitate regular monitoring.
    [Show full text]
  • Drug Consumption in Current Year (Period 201901
    Page 1 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A ALIMENTARY TRACT AND METABOLISM 323,80 3 4 321 589 7 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01AA Caries prophylactic agents 11,90 3 14 663 8 9 A01AA01 sodium fluoride 11,90 3 14 610 8 10 A01AA03 olaflur - - - 53 1 -2 A01AB Antiinfectives for local oral treatment 2,36 8 2 1 266 10 15 A01AB03 chlorhexidine 2,02 6 -3 930 6 5 A01AB11 various 0,33 21 57 335 21 55 A01AB22 doxycycline - - - 0 - -100 A01AC Corticosteroids for local oral treatment - - - 113 1 -26 A01AC01 triamcinolone - - - 113 1 -26 A01AD Other agents for local oral treatment 0,02 0 -28 49 0 -32 A01AD02 benzydamine 0,02 0 -28 49 0 -32 A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 3 30 885 4 -5 A02A ANTACIDS 2,23 1 1 3 681 1 3 A02AA Magnesium compounds 0,07 22 -7 141 22 -7 A02AA04 magnesium hydroxide 0,07 22 -7 141 22 -7 A02AD Combinations and complexes of aluminium, 2,17 0 1 3 539 0 4 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 1 3 539 0 4 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 3 27 205 5 -7 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 -77 551 10 -29 A02BA02 ranitidine 0,00 1 -100 1 1 -100 A02BA03 famotidine 0,16 7 48 550 10 43 A02BB Prostaglandins 0,04 62 55 80 62 55 A02BB01 misoprostol 0,04 62 55 80 62 55 A02BC Proton pump inhibitors 69,26 3 4 23 531 4 -8
    [Show full text]
  • Reversal Agents
    R E V E R S A L A G E N T S Opioids Nalaxone (Narcan) Opioid effects may outlast the reversal's duration of action Continue monitoring 3-4 hrs Benzodiazepines Flumazenil (Romazicon) May lower seizure threshold May cause confusion, agitation, hypertension, and alterations in heart rate Beta Blockers Glucagon Monitor for hyperglycemia May cause hypokalemia Heparin Protamine Sulfate May cause hypotension Risk for anaphylaxis Has weak anticoagulant effect Risk for thrombotic event Warfarin PCC - Vitamin K - FFP Treatment based on severity of bleeding An exhibitImiomne tdoiauter - oPnCC R aandp Vhita Kel Joo's mostF aisct o- FnFiPc works! Within 6 hrs - Vitamin K Risk for thrombotic event Factor Xa Inhibitors Andexanet alfa Risk for thrombotic event May cause cardiogenic shock, heart failure exacerbations, UTI, acute respiratory failure, and pneumonia © Digital Health Media LLC R E F E R E N C E S APSF. (2018, August 5). New Factor Xa Inhibitor (Xarelto®) (Eliquis®) Reversal Agent. Retrieved from Anesthesia Patient Safety Foundation website: https://www.apsf.org/news- updates/new-factor-xa-inhibitor-xarelto-eliquis-reversal-agent/ CHEMM. (n.d.). Naloxone. Retrieved from https://chemm.nlm.nih.gov/countermeasure _naloxone.htm#adminHanley, Deglin, J. H., & Vallerand, A. H. (2007). Davis’s drug guide for nurses (11th ed.). Philadelphia, PA: F. A. Davis Company J. P. (2004). Warfarin reversal. Journal of Clinical Pathology, 57(11), 1132–1139 https://doi.org /10.1136/jcp.2003.008904 Kang, M., & Ghassemzadeh, S. (2019). Benzodiazepine Toxicity. In StatPearls. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK482238/ Ni Ainle, F., Preston, R.
    [Show full text]